胃、十二指肠和结直肠癌中68Ga-FAPI与18F-FDG摄取比较
该回顾性研究纳入35例胃、十二指肠和结直肠癌患者,比较同期68Ga-FAPI与18F-FDG PET/CT对原发灶和转移灶的诊断效能。68Ga-FAPI在原发灶、淋巴结及骨和内脏转移灶的摄取和敏感度均高于18F-FDG,在19例初治患者中使4例(21%)临床TNM分期上调。
要点
- 68Ga-FAPI PET/CT对胃、十二指肠和结直肠癌原发灶及转移灶的敏感度高于18F-FDG PET/CT。
- 68Ga-FAPI在多数原发灶和转移灶的示踪剂摄取高于18F-FDG。
- 在初治患者中,68Ga-FAPI较18F-FDG使21%(4/19)患者临床TNM分期上调。
诊断标准与关键数值
- 68Ga-FAPI PET/CT与18F-FDG PET/CT诊断原发肿瘤的敏感度分别为100%(19/19)与53%(10/19),P=0.004。
- 68Ga-FAPI PET/CT与18F-FDG PET/CT诊断淋巴结的敏感度分别为79%(22/28)与54%(15/28),P<0.001。
- 68Ga-FAPI PET/CT与18F-FDG PET/CT诊断骨和内脏转移的敏感度分别为89%(31/35)与57%(20/35),P<0.001。
- 原发灶摄取(胃癌)68Ga-FAPI 12.7 vs 18F-FDG 3.7,P=0.003;原发灶摄取(结直肠癌)68Ga-FAPI 15.9 vs 18F-FDG 7.9,P=0.03。
- 转移灶摄取:淋巴结68Ga-FAPI 6.7 vs 18F-FDG 2.4,P<0.001;肝转移9.7 vs 5.2,P<0.001;腹膜转移8.4 vs 3.6,P<0.001;骨转移4.3 vs 2.2,P<0.001;肺转移4.4 vs 1.9,P=0.01。
临床应用与阅片要点
- 在胃、十二指肠和结直肠癌的PET/CT阅片与报告中,可参考68Ga-FAPI对原发灶、淋巴结及骨和内脏转移灶的检出敏感度高于18F-FDG的研究结果。
- 对初治患者,68Ga-FAPI PET/CT可提供较18F-FDG PET/CT更高的临床TNM分期信息(4/19,21%患者分期上调)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Accurate clinical staging is crucial to managing gastrointestinal cancer, but fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT has limitations. Targeting fibroblast-activation protein is a newer diagnostic approach for the visualization of tumor stroma, and gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitors (FAPIs), hereafter 68Ga-FAPIs, present a promising alternative to 18F-FDG. Purpose To compare the diagnostic efficacy of 68Ga-FAPI PET/CT in primary and metastatic lesions of gastrointestinal malignancies with that of 18F-FDG PET/CT. Materials and Methods Images from patients with gastric, duodenal, and colorectal cancers who underwent contemporaneous 18F-FDG and 68Ga-FAPI PET/CT between October 2019 through June 2020 were retrospectively analyzed. 18F-FDG and 68Ga-FAPI uptakes were compared by using the Wilcoxon signed-rank test. The McNemar test was used to compare the diagnostic performance between the two techniques. Results Thirty-five patients (median age, 64 years [interquartile range, 53-68 years]; 18 men) were evaluated. In treatment-naive patients (n = 19), 68Ga-FAPI PET/CT led to upstaging of the clinical TNM stage in four (21%) patients compared with 18F-FDG PET/CT. Tracer uptake was higher with 68Ga-FAPI PET/CT than with 18F-FDG PET/CT in primary lesions (gastric cancer: 12.7 vs 3.7, respectively, P = .003; colorectal cancer: 15.9 vs 7.9, P = .03), involved lymph nodes (6.7 vs 2.4, P < .001), and bone and visceral metastases (liver metastases: 9.7 vs 5.2, P < .001; peritoneal metastases: 8.4 vs 3.6, P < .001; bone metastases: 4.3 vs 2.2, P < .001; lung metastases: 4.4 vs 1.9, P = .01). In addition, the sensitivity of 68Ga-FAPI PET/CT was higher than that of 18F-FDG PET/CT in the detection of primary tumors (100% [19 of 19] vs 53% [10 of 19], respectively; P = .004), lymph nodes (79% [22 of 28] vs 54% [15 of 28], P < .001), and bone and visceral metastases (89% [31 of 35] vs 57% [20 of 35], P < .001). Conclusion Gallium 68 fibroblast-activation protein inhibitor PET/CT was superior to fluorine 18 fluorodeoxyglucose PET/CT in the detection of primary and metastatic lesions in gastric, duodenal, and colorectal cancers, with higher tracer uptake in most primary and metastatic lesions. Published under a CC BY 4.0 license.
引用
- Pang Y, Zhao L, Luo Z, et al. Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. Radiology. 2020. PMID: 33258746. doi:10.1148/radiol.2020203275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。